Dr Stageman has a wealth of experience in the pharmaceutical industry and biotechnology research. He has held a number of international R&D senior management roles at AstraZeneca, from drug discovery through to global clinical development. Latterly he led the team responsible for developing AstraZeneca’s competitive biopharmaceutical strategy, resulting in the acquisition of Cambridge Antibody Technology and of MedImmune. After a period as General Manager of MedImmune Cambridge, Dr Stageman returned to AstraZeneca as Vice President of UK Science Affairs before retiring in 2011.

Dr Stageman was formerly Chair of the HealthTech and Medicines Knowledge Transfer Network for the Technology Strategy Board (TSB) and a Council member of the Biotechnology and Biological Sciences Research Council (BBSRC). He is Chair of the Major Awards Committee of the Biomedical Catalyst on behalf of the MRC and TSB, and is currently a lay Governor of the University of Manchester where he is also an Honorary Professor of Life Sciences.

John was awarded the OBE for his services to the UK Biotechnology Industry in the 2011 New Year’s Honours list.

Back to our trustees